Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
Authors
Keywords
-
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 89, Issue 6, Pages 761-772
Publisher
Springer Science and Business Media LLC
Online
2022-04-21
DOI
10.1007/s00280-022-04428-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2020) Boris Bikbov et al. LANCET
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- NCCN Guidelines Insights: Kidney Cancer, Version 1.2021
- (2020) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer
- (2020) T. Powles ANNALS OF ONCOLOGY
- Biopsy-based estimation of total nephron number in Japanese living kidney donors
- (2019) Takaya Sasaki et al. Clinical and Experimental Nephrology
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
- (2018) Katsunori Tatsugami et al. Oncotarget
- Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018
- (2018) Clinical and Experimental Nephrology
- Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study
- (2018) Cristina Masini et al. Clinical Genitourinary Cancer
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review]
- (2016) Yasuhiro Ito et al. ENDOCRINE JOURNAL
- Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
- (2016) Shuichi Kaneko et al. JOURNAL OF GASTROENTEROLOGY
- Selective use of sorafenib in the treatment of thyroid cancer
- (2016) Fabián Pitoia et al. Drug Design Development and Therapy
- Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)
- (2015) V. Launay-Vacher et al. ANNALS OF ONCOLOGY
- Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency
- (2015) Alexandr Poprach et al. EUROPEAN JOURNAL OF CANCER
- A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance
- (2015) Hideyuki Akaza et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib in Radioiodine-Refractory Thyroid Cancer
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents
- (2015) Hideaki Miyake et al. Targeted Oncology
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Kidney Diseases Associated With Anti-Vascular Endothelial Growth Factor (VEGF)
- (2014) Hassan Izzedine et al. MEDICINE
- Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2012 Clinical Practice Guideline
- (2013) Paul E. Stevens ANNALS OF INTERNAL MEDICINE
- Association of albuminuria and reduced estimated glomerular filtration rate with incident stroke and coronary artery disease in patients with type 2 diabetes
- (2010) Ryotaro Bouchi et al. HYPERTENSION RESEARCH
- Chronic Kidney Disease as an Independent Risk for Long-Term Adverse Outcomes in Patients Hospitalized With Heart Failure in Japan
- (2009) Sanae Hamaguchi et al. CIRCULATION JOURNAL
- Hypertension and proteinuria: a class-effect of antiangiogenic therapies
- (2008) Vincent Launay-Vacher et al. ANTI-CANCER DRUGS
- FDA Approves Sorafenib for Patients With Inoperable Liver Cancer
- (2008) Les Lang GASTROENTEROLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started